Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients
F. Maltais, E. Beck, D. Webster, M. R. Maleki-Yazdi, J. V. Seibt, A. Arnoux, A. Hamilton (Toronto, Burlington, Canada; Rüdersdorf, Germany; Killeen, United States Of America; Reims, France)
Source: Annual Congress 2010 - Bronchodilators in airways disease
Session: Bronchodilators in airways disease
Session type: Oral Presentation
Number: 5557
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Maltais, E. Beck, D. Webster, M. R. Maleki-Yazdi, J. V. Seibt, A. Arnoux, A. Hamilton (Toronto, Burlington, Canada; Rüdersdorf, Germany; Killeen, United States Of America; Reims, France). Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010; 36: Suppl. 54, 5557
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Superior spirometric efficacy of single dose formoterol compared to single dose salmeterol during the first hour post-dose in moderate and severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 57s Year: 2001
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 457s Year: 2007
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
Comparable efficacy and tolerability of formoterol 12 μg or 24 μg twice daily in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 51s Year: 2005
Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001
Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020